The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Coherus BioSciences Inc. (CHRS) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.06, or 1.38%, to $4.40. The Coherus BioSciences Inc. has recorded 22,994 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Coherus Announces U.S. Launch of UDENYCA® Autoinjector.
<25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Coherus BioSciences Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $4.34 and fluctuated between $4.5624 as its day high and $4.3100 as its day low. The current market capitalization of Coherus BioSciences Inc. is $347.29M. A total of 2.3 million shares were traded on the day, compared to an average of 1.56M shares.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for CHRS in the last 3 months, the mean price target is $15.00 with high estimates of $24.00 and low estimates of $8.00. In terms of 52-week highs and lows, CHRS has a high of $14.11 and a low of $4.36.
As of this writing, CHRS has an earnings estimate of -$0.62 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.45 per share and a lower estimate of -$1.03. The company reported an EPS of -$0.6 in the last quarter, which was 28.60% higher than expectations of -$0.84.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. CHRS’s latest balance sheet shows that the firm has $417.19M in Cash & Short Term Investments as of fiscal 2021. There were $408.28M in debt and $79.03M in liabilities at the time. Its Book Value Per Share was -$2.48, while its Total Shareholder’s Equity was $97.73M.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CHRS is Buy with a score of 4.56.